Immune Design to Present at Upcoming Investor Conferences

SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that senior management will present at upcoming investor conferences.

Leerink Partners 7th Annual Global Healthcare ConferenceThursday, February 15, 2018 at 9:30 a.m. Eastern Time in New York.

RBC Capital Markets 2018 Global Healthcare Conference Wednesday, February 21, 2018 at 4:05 p.m. Eastern Time in New York.

Cowen & Company 38th Annual Health Care ConferenceMonday, March 12, 2018 at 12:00 p.m. Eastern Time in Boston.

A live webcast of each presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of each presentation will be available on the company website for 30 days.

About Immune Design

Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases. CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company’s two technology platforms that are potent stimulators of the immune system: ZVex® and GLAAS®.  Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.

Media ContactJulie RathbunRathbun Communications[email protected]206-769-9219

Investor ContactSylvia Wheeler[email protected]

You May Also Be Interested In

• TD Cowen Starts Alliant Energy (LNT) at Hold (correction)
• BTQ Technologies Completes Acquisition of QPerfect, Advancing Its Mission of Building Trusted Quantum Technologies With World-Class Emulation, Digital Twin, and Control Capabilities
• Storaktionærmeddelelse